Print

HIVNET 026

A Multisite Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of ALVAC-HIV vCP1452 Alone and Combined with MN rgp120

Trial Details:

II Completed
National Institute of Allergy and Infectious Diseases (NIAID) June 01, 2000
ALVAC vCP1452,MN rgp120 Canarypox gp120, TM gp41, gag, protease, nef, pol MN/LAI; Protein Env gp120 B
ALVAC vCP1452 Viral Vector - Pox
MN rgp120 Protein
Brazil, Haiti, Peru, Trinidad & Tobago 200
http://www.clinicaltrials.gov; http://www.actis.org http://www.clinicaltrials.gov; http://www.actis.org